| 2025-04-28 | -36.6% | earnings | Seeking Alpha | NeoGenomics Q1 2025 Earnings Preview |
| 2025-04-29 | -36.5% | expansion | Seeking Alpha | NeoGenomics targets 25% annual NGS growth with new product launches in 2025 |
| 2025-04-29 | -36.5% | earnings | Seeking Alpha | NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript |
| 2025-04-29 | -36.5% | earnings | Seeking Alpha | NeoGenomics drops as sequential revenue decline leads to Q1 miss |
| 2025-04-29 | -36.5% | earnings | Seeking Alpha | NeoGenomics, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-04-29 | -36.5% | earnings | Seeking Alpha | NeoGenomics Non-GAAP EPS of $0.00 beats by $0.01, revenue of $168.04M misses by $2.86M |
| 2025-04-29 | -36.5% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2025-04-29 | -36.5% | news | Yahoo Finance | Why NeoGenomics (NEO) Stock Is Nosediving - Yahoo Finance |
| 2022-03-28 | -31.0% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-01-10 | -30.8% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-05-09 | +27.6% | earnings | Seeking Alpha | NeoGenomics stock surges as BTIG upgrades after Q1 beat (NASDAQ:NEO) - Seeking Alpha |
| 2022-11-08 | +24.6% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2025-08-29 | +23.5% | news | Seeking Alpha | NeoGenomics rallies after court win in Natera patent dispute |
| 2025-08-29 | +23.5% | news | Yahoo Finance | Why Is NeoGenomics (NEO) Stock Soaring Today - Yahoo Finance |
| 2025-08-29 | +23.5% | news | Seeking Alpha | NeoGenomics stock up on court win over Natera (NEO:NASDAQ) - Seeking Alpha |
| 2025-08-29 | +23.5% | news | Yahoo Finance | NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims - Yahoo Finance |
| 2025-07-29 | -20.7% | earnings | Seeking Alpha | NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch |
| 2025-07-29 | -20.7% | earnings | Seeking Alpha | NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript |
| 2025-07-29 | -20.7% | earnings | Seeking Alpha | NeoGenomics, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-07-29 | -20.7% | earnings | Seeking Alpha | NeoGenomics Non-GAAP EPS of $0.03 beats by $0.01, revenue of $181.3M misses by $1.34M |
| 2025-07-29 | -20.7% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-11-07 | +20.2% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-05-08 | +19.6% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2023-02-23 | +18.7% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2025-05-01 | +18.1% | news | Seeking Alpha | NeoGenomics pays off 1.25% convertible senior notes |
| 2024-07-29 | +16.5% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2024-07-29 | +16.5% | legal | Stock Titan | NeoGenomics Reports Second Quarter 2024 Results - Stock Titan |
| 2025-07-28 | -16.2% | earnings | Seeking Alpha | NeoGenomics Q2 2025 Earnings Preview |
| 2024-02-20 | +15.2% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-08-09 | +14.4% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-05-06 | -13.5% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2022-04-27 | -13.0% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2026-02-18 | -12.7% | news | Yahoo Finance | Why NeoGenomics (NEO) Shares Are Falling Today - Yahoo Finance |
| 2026-02-18 | -12.7% | news | Stock Titan | Stream NeoGenomics' March oncology diagnostics talks from two investor events - Stock Titan |
| 2022-07-21 | +12.5% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2021-05-05 | -12.4% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2021-05-05 | -12.4% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2021-05-05 | -12.4% | legal | SEC EDGAR | NEO 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2025-02-18 | -12.3% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2021-11-04 | -11.9% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-02-23 | +11.5% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-05-07 | -10.8% | analyst | eToro | NeoGenomics Inc. (NEO.US) Stock Price, News & Analyst Forecast - eToro |
| 2026-02-17 | -10.5% | earnings | Seeking Alpha | NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction |
| 2026-02-17 | -10.5% | earnings | Seeking Alpha | NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript |
| 2026-02-17 | -10.5% | earnings | Seeking Alpha | NeoGenomics, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-17 | -10.5% | earnings | Seeking Alpha | NeoGenomics Non-GAAP EPS of $0.06 beats by $0.02, revenue of $190.17M beats by $1.89M |
| 2026-02-17 | -10.5% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2026-02-17 | -10.5% | earnings | Yahoo Finance | NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance |
| 2026-02-17 | -10.5% | earnings | TradingView | NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates - TradingView |
| 2026-02-17 | -10.5% | news | Kalkine Media | How NeoGenomics (NASDAQ:NEO) Performs Amid Fluctuations In Nasdaq Today - Kalkine Media |
| 2022-05-16 | -10.4% | legal | SEC EDGAR | NEO 8-K: 8.01 and (SEC Filing) |
| 2025-04-30 | +9.6% | earnings | Seeking Alpha | NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) |
| 2023-11-06 | +9.0% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2025-10-27 | -8.5% | earnings | Seeking Alpha | NeoGenomics Q3 2025 Earnings Preview |
| 2022-05-11 | +7.6% | legal | SEC EDGAR | NEO 8-K: 5.02 and (SEC Filing) |
| 2026-01-05 | +7.6% | news | Stock Titan | Cancer diagnostics firm NeoGenomics joins major J.P. Morgan event - Stock Titan |
| 2021-09-13 | -7.1% | news | The Motley Fool | NeoGenomics - NEO - Stock Price & News - The Motley Fool |
| 2025-08-27 | +7.0% | news | simplywall.st | Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt? - simplywall.st |
| 2022-10-08 | -6.6% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for NeoGenomics (NEO) - Zacks Investment Research |
| 2026-01-13 | +6.5% | news | Seeking Alpha | NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha |
| 2026-01-13 | +6.5% | analyst | The Globe and Mail | Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO) - The Globe and Mail |
| 2026-04-14 | +6.5% | news | Simply Wall St. | Neo Silmet Facility Advances European Rare Earth Magnet Supply Chain |
| 2022-04-14 | -6.5% | legal | SEC EDGAR | NEO 8-K: 8.01 and (SEC Filing) |
| 2025-10-14 | +6.4% | news | DirectorsTalk Interviews | NeoGenomics, Inc. (NEO) Stock Analysis: A Healthcare Diagnostics Player with a 7% Upside Potential - DirectorsTalk Interviews |
| 2026-04-13 | +6.4% | earnings | StockStory | A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack |
| 2026-04-13 | +6.4% | news | Stock Titan | NeoGenomics brings 9 cancer studies, including AI research, to AACR - Stock Titan |
| 2024-04-30 | -6.4% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2024-11-05 | +5.6% | legal | SEC EDGAR | NEO 8-K: 2.02, 5.02 (SEC Filing) |
| 2025-07-22 | +5.6% | news | TradingView | NEO Options Chain — NASDAQ:NEO - TradingView |
| 2022-10-20 | -5.4% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-04-16 | -5.3% | earnings | MarketBeat | NeoGenomics (NASDAQ:NEO) Stock Price Down 5.3% - Here's What Happened - MarketBeat |
| 2026-02-25 | +5.1% | news | Stock Titan | New cancer blood test aims to spot tumor relapse before scans do - Stock Titan |
| 2023-08-08 | -5.1% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2026-01-23 | -4.7% | news | simplywall.st | Don't Ignore The Insider Selling In NeoGenomics - simplywall.st |
| 2021-08-06 | -4.7% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2022-01-19 | -4.4% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-03-03 | -4.0% | executive | Stock Titan | Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan |
| 2026-03-03 | -4.0% | news | Stock Titan | Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan |
| 2026-03-31 | +4.0% | news | AD HOC NEWS | NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands - AD HOC NEWS |
| 2025-03-31 | -3.8% | legal | SEC EDGAR | NEO 8-K: 5.02 and (SEC Filing) |
| 2024-02-26 | -3.7% | legal | SEC EDGAR | NEO 8-K: 5.02 and (SEC Filing) |
| 2025-07-15 | -3.7% | news | DirectorsTalk Interviews | NeoGenomics, Inc. (NEO) Stock Analysis: Navigating the Diagnostics Market with 56.69% Potential Upside - DirectorsTalk Interviews |
| 2026-03-16 | +3.7% | news | Investing.com | William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision - Investing.com |
| 2026-03-16 | +3.7% | news | Investing.com | Neogenomics stock gets Medicare coverage for blood-based test - Investing.com |
| 2026-03-16 | +3.7% | news | Stock Titan | Medicare to cover NeoGenomics blood test profiling over 500 genes - Stock Titan |
| 2026-03-16 | +3.7% | news | Investing.com | Neogenomics stock gets MolDX reimbursement for cancer test - Investing.com |
| 2026-03-16 | +3.7% | news | TradingView | NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - TradingView |
| 2025-07-16 | -3.6% | news | simplywall.st | NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st |
| 2025-12-30 | -3.5% | legal | SEC EDGAR | NEO 8-K: 5.02 and (SEC Filing) |
| 2025-12-30 | -3.5% | news | Benzinga | Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga |
| 2026-01-25 | -3.5% | news | Seeking Alpha | NeoGenomics: Distribution Moat In Community Oncology |
| 2026-01-25 | -3.5% | news | Seeking Alpha | NeoGenomics: Distribution Moat In Community Oncology (NASDAQ:NEO) - Seeking Alpha |
| 2026-04-15 | -3.3% | news | Simply Wall St. | Is It Too Late To Consider Neo Performance Materials (TSX:NEO) After A 118% Rally? |
| 2022-03-09 | -3.2% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2022-09-04 | +3.0% | analyst | TradingView | NEO Forecast — Price Target — Prediction for 2027 - TradingView |
| 2022-08-12 | +2.9% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2022-11-18 | +2.6% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2021-06-08 | +2.6% | legal | SEC EDGAR | NEO 8-K: 8.01 (SEC Filing) |
| 2025-03-19 | +2.5% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2021-07-29 | +2.5% | earnings | Zacks Investment Research | What date does NeoGenomics's (NEO) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2021-06-24 | +2.4% | legal | SEC EDGAR | NEO 8-K: 2.01, 3.02, 5.02, 7.01 (SEC Filing) |
| 2023-06-29 | -2.3% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-01-23 | +2.2% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-02-13 | +2.2% | earnings | Seeking Alpha | NeoGenomics Q4 2025 Earnings Preview |
| 2021-07-15 | +2.2% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2021-10-12 | +2.2% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-02 | -2.1% | executive | Stock Titan | NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan |
| 2022-07-18 | -2.0% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2024-03-31 | -1.9% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-01-12 | -1.7% | earnings | Seeking Alpha | NeoGenomics sees Q4 revenue of about $190M |
| 2026-01-12 | -1.7% | legal | SEC EDGAR | NEO 8-K: 2.02, 5.02 (SEC Filing) |
| 2026-01-12 | -1.7% | executive | marketscreener.com | NeoGenomics, Inc. Announces Chief Financial Officer Changes - marketscreener.com |
| 2025-04-01 | -1.7% | executive | Seeking Alpha | NeoGenomics announces CEO transition |
| 2023-05-17 | -1.4% | legal | SEC EDGAR | NEO 8-K: 5.02 and (SEC Filing) |
| 2025-05-27 | -1.4% | legal | SEC EDGAR | NEO 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-06-24 | +1.3% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-11-10 | -1.3% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-04-22 | -1.2% | earnings | Motley Fool | NeoGenomics (NEO) Q4 2024 Earnings Transcript |
| 2026-04-22 | -1.2% | earnings | StockStory | 3 Unprofitable Stocks Walking a Fine Line |
| 2026-04-22 | -1.2% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Is NeoGenomics (NEO) stock showing signs of reversal | Q4 2025: EPS Exceeds Expectations - Wall Street Views - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-22 | -1.2% | news | Stock Titan | NEO Financials: Income Statement, Balance Sheet & Cash Flow | Neogenomics Inc - Stock Titan |
| 2026-04-18 | -1.2% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Is NeoGenomics (NEO) stock forming lower lows (Bullish Momentum) 2026-04-18 - Low Risk Entry - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-02-26 | +1.1% | news | Yahoo Finance | 3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Yahoo Finance |
| 2025-03-18 | +1.1% | executive | Seeking Alpha | NeoGenomics names Warren Stone as chief operating officer |
| 2025-03-18 | +1.1% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2022-04-25 | -1.1% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-04-23 | +1.0% | news | StockStory | 2 Healthcare Stocks Worth Your Attention and 1 We Ignore |
| 2026-04-23 | +1.0% | news | Exec Edge | SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases |
| 2026-04-23 | +1.0% | news | Business Wire | NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration |
| 2026-04-23 | +1.0% | news | Stock Titan | Cancer doctors can order NeoGenomics tests inside Epic records - Stock Titan |
| 2026-04-21 | -1.0% | earnings | MarketBeat | NeoGenomics (NEO) Projected to Post Earnings on Tuesday - MarketBeat |
| 2026-01-21 | +0.9% | news | Investing.com | Neogenomics pres. Stone sells $277k in NEO stock - Investing.com |
| 2024-05-11 | -0.9% | earnings | MarketBeat | NeoGenomics (NEO) Stock Forecast and Price Target 2026 $NEO - MarketBeat |
| 2025-10-28 | +0.9% | earnings | Seeking Alpha | NeoGenomics outlines $30B MRD market pursuit and reiterates 2025 growth targets amid record clinical revenue |
| 2025-10-28 | +0.9% | earnings | Seeking Alpha | NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript |
| 2025-10-28 | +0.9% | earnings | Seeking Alpha | NeoGenomics, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-10-28 | +0.9% | earnings | Seeking Alpha | NeoGenomics Non-GAAP EPS of $0.03 beats by $0.01, revenue of $187.8M beats by $3.95M |
| 2025-10-28 | +0.9% | legal | SEC EDGAR | NEO 8-K: 2.02 and (SEC Filing) |
| 2025-10-28 | +0.9% | news | Yahoo Finance | Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance |
| 2025-10-28 | +0.9% | earnings | Yahoo Finance | NeoGenomics’s (NASDAQ:NEO) Q3 Sales Top Estimates, Stock Soars - Yahoo Finance |
| 2025-10-28 | +0.9% | earnings | Quiver Quantitative | NEOGENOMICS Earnings Results: $NEO Reports Quarterly Earnings | NEO Stock News - Quiver Quantitative |
| 2025-10-28 | +0.9% | earnings | Yahoo Finance | NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance |
| 2025-10-28 | +0.9% | earnings | Seeking Alpha | NeoGenomics, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:NEO) 2025-10-28 - Seeking Alpha |
| 2025-03-21 | +0.8% | news | Intellectia AI | NEO Forecast — Price Prediction for 2026. Should I Buy NEO? - Intellectia AI |
| 2024-02-23 | -0.8% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-01-27 | -0.8% | news | Stock Titan | Oncology diagnostics firm NeoGenomics sets Feb. 17 results call - Stock Titan |
| 2025-05-22 | +0.8% | expansion | Investing.com UK | NeoGenomics launches rapid c-MET diagnostic test for NSCLC By Investing.com - Investing.com UK |
| 2025-07-02 | +0.6% | earnings | Yahoo Finance | Here’s Why NeoGenomics (NEO) Sold Off in Q1 - Yahoo Finance |
| 2026-01-14 | -0.6% | news | Seeking Alpha | NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-14 | -0.6% | news | Seeking Alpha | NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2025-08-08 | +0.5% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-03-20 | -0.3% | news | simplywall.st | Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO) - simplywall.st |
| 2022-12-06 | -0.3% | legal | SEC EDGAR | NEO 8-K: 5.02, 7.01 (SEC Filing) |
| 2021-07-07 | +0.2% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-04-06 | +0.2% | executive | Quiver Quantitative | NEOGENOMICS INC ($NEO) CEO 2025 Pay Revealed | NEO Stock News - Quiver Quantitative |
| 2026-04-06 | +0.2% | earnings | MarketBeat | Aberdeen Group plc Buys 1,006,676 Shares of NeoGenomics, Inc. $NEO - MarketBeat |
| 2026-04-03 | -0.2% | executive | Stock Titan | NeoGenomics (NEO) CEO exercises RSUs and uses shares to cover taxes - Stock Titan |
| 2026-04-03 | -0.2% | executive | Stock Titan | NeoGenomics (NEO) COO nets shares after 17,562-unit RSU vesting - Stock Titan |
| 2026-04-03 | -0.2% | news | AD HOC NEWS | NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics - AD HOC NEWS |
| 2026-04-03 | -0.2% | news | AD HOC NEWS | NeoGenomics Inc stock: Precision oncology leader facing growth hurdles - AD HOC NEWS |
| 2025-01-15 | -0.2% | legal | SEC EDGAR | NEO 8-K: 5.02 and 7.01 (SEC Filing) |
| 2026-04-17 | -0.1% | news | Simply Wall St. | A Look At Neo Performance Materials (TSX:NEO) Valuation After New European Heavy Rare Earth Line Reaches First Output |
| 2026-04-07 | -0.1% | earnings | Stock Titan | NeoGenomics shifts quarterly earnings calls to after market close - Stock Titan |
| 2026-02-20 | -0.1% | news | Yahoo Finance | After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Yahoo Finance |
| 2024-04-18 | -0.0% | legal | SEC EDGAR | NEO 8-K: 5.02 (SEC Filing) |
| 2026-04-25 | — | news | StockStory | Why NeoGenomics (NEO) Stock Is Trading Up Today |
| 2026-04-25 | — | news | Yahoo Finance | Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance |
| 2026-04-25 | — | news | simplywall.st | How NeoGenomics’ Epic Aura Integration Could Reshape Test Adoption For NEO Investors - simplywall.st |